ATE466081T1 - Zusammensetzungen und verfahren zur regulierung eines komplementsystems - Google Patents

Zusammensetzungen und verfahren zur regulierung eines komplementsystems

Info

Publication number
ATE466081T1
ATE466081T1 AT06850425T AT06850425T ATE466081T1 AT E466081 T1 ATE466081 T1 AT E466081T1 AT 06850425 T AT06850425 T AT 06850425T AT 06850425 T AT06850425 T AT 06850425T AT E466081 T1 ATE466081 T1 AT E466081T1
Authority
AT
Austria
Prior art keywords
complement pathway
compositions
regulating
methods
complement system
Prior art date
Application number
AT06850425T
Other languages
English (en)
Inventor
Samuel Jotham Reich
Nadine Dejneka
Original Assignee
Opko Ophthalmics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Ophthalmics Llc filed Critical Opko Ophthalmics Llc
Application granted granted Critical
Publication of ATE466081T1 publication Critical patent/ATE466081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT06850425T 2005-12-22 2006-12-22 Zusammensetzungen und verfahren zur regulierung eines komplementsystems ATE466081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75304105P 2005-12-22 2005-12-22
PCT/US2006/062568 WO2007089375A2 (en) 2005-12-22 2006-12-22 Compositions and methods for regulating complement system

Publications (1)

Publication Number Publication Date
ATE466081T1 true ATE466081T1 (de) 2010-05-15

Family

ID=38234879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850425T ATE466081T1 (de) 2005-12-22 2006-12-22 Zusammensetzungen und verfahren zur regulierung eines komplementsystems

Country Status (11)

Country Link
US (1) US20070178068A1 (de)
EP (2) EP1966379B1 (de)
JP (1) JP2009521234A (de)
AT (1) ATE466081T1 (de)
AU (1) AU2006337093B2 (de)
CA (1) CA2634286A1 (de)
DE (1) DE602006014026D1 (de)
IL (2) IL192282A (de)
MX (1) MX2008008302A (de)
NZ (1) NZ569368A (de)
WO (1) WO2007089375A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482903A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2007095154A2 (en) * 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
EP2148691B1 (de) * 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analoga zur behandlung von entzündungserkrankungen der atemwege
US8940299B2 (en) * 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
HRP20160261T1 (hr) * 2008-07-10 2016-06-03 Regenesance B.V. Komplementarni antagonisti i njihova uporaba
WO2010042530A2 (en) * 2008-10-06 2010-04-15 Baylor College Of Medicine Nlrc5 as a target for immune therapy
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
CA2745832A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
EP2756845B1 (de) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
MX382900B (es) * 2013-12-12 2025-03-13 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ÁCIDO RIBONUCLEICO DE INTERFERENCIA (ARNi) CONTRA EL COMPONENTE DEL COMPLEMENTO Y MÉTODOS PARA SU USO.
WO2016022914A1 (en) * 2014-08-08 2016-02-11 Moderna Therapeutics, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
HK1245010A1 (zh) 2014-12-10 2018-08-24 明尼苏达大学董事会 用於治疗疾病的遗传修饰的细胞、组织和器官
EP3405577B8 (de) 2016-01-20 2023-02-15 396419 B.C. Ltd. Zusammensetzungen und verfahren zur hemmung des faktors d
WO2018075373A1 (en) * 2016-10-17 2018-04-26 Apellis Pharmaceuticals, Inc. Combination therapy for c3 inhibition
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
SG11202002940QA (en) * 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CN114981430A (zh) * 2019-08-27 2022-08-30 赛伦斯治疗有限责任公司 用于抑制细胞中的c3表达的核酸
JP7676377B2 (ja) 2019-10-22 2025-05-14 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分Ｃ３ ｉＲＮＡ組成物およびその使用方法
CA3230589A1 (en) 2021-09-02 2023-03-09 Sibylle DAMES Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
JP2024541989A (ja) 2021-10-29 2024-11-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
WO2023186056A1 (zh) * 2022-04-02 2023-10-05 上海舶望制药有限公司 用于抑制补体成分c3蛋白表达的组合物和方法
EP4608413A2 (de) 2022-10-27 2025-09-03 Arrowhead Pharmaceuticals, Inc. Rnai-mittel zur hemmung der expression der komplementkomponente c3 (c3), pharmazeutische zusammensetzungen davon und verfahren zur verwendung
JPWO2025143000A1 (de) * 2023-12-27 2025-07-03

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20030096775A1 (en) * 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7816497B2 (en) * 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
CA2670801A1 (en) * 2005-11-30 2007-06-07 Intradigm Corporation Compositions and methods of using sirna to knockdown gene expression and to improve solid organ and cell transplantation

Also Published As

Publication number Publication date
WO2007089375A2 (en) 2007-08-09
IL192282A0 (en) 2008-12-29
MX2008008302A (es) 2009-01-21
EP2221378A1 (de) 2010-08-25
EP1966379A2 (de) 2008-09-10
WO2007089375A3 (en) 2007-12-06
AU2006337093B2 (en) 2013-03-14
EP2221378B1 (de) 2013-04-17
EP1966379B1 (de) 2010-04-28
AU2006337093A1 (en) 2007-08-09
DE602006014026D1 (de) 2010-06-10
US20070178068A1 (en) 2007-08-02
NZ569368A (en) 2011-11-25
IL223632A0 (en) 2013-02-03
IL192282A (en) 2012-12-31
JP2009521234A (ja) 2009-06-04
CA2634286A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
ATE466081T1 (de) Zusammensetzungen und verfahren zur regulierung eines komplementsystems
MX378700B (es) Variantes derivadas de actriib y usos de las mismas.
BRPI0519508A2 (pt) análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
DE502005011119D1 (de)
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
MX2010006422A (es) Proteinas de union a antigenos.
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2007109097A3 (en) RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
EP3351211C0 (de) Sklerale prothese zur behandlung von altersweitsichtigkeit und anderen augenerkrankungen
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
MX2012004638A (es) Modulacion de degeneracion de axones.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
ATE404188T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
DE602005011943D1 (de) Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
ECSP056142A (es) Formulaciones de anticuerpos y proteínas de alta concentración
AR036401A1 (es) Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
EP4327875A3 (de) Tiermodelle und screening-verfahren für intraokulare erkrankungen oder störungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE485047T1 (de) Verwendung eines wachstumsstimulierenden proteins
DOP2007000020A (es) Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties